210037-58-4

Basic information

• Product Name: METHYL 5-BROMOPYRAZINE-2-CARBOXYLATE
• Synonyms: METHYL 5-BROMOPYRAZINE-2-CARBOXYLATE;5-Bromo-2-pyrazinecarboxylic acid methyl ester;5-Bromopyrazinecarboxylic acid methyl ester;2-Pyrazinecarboxylic acid, 5-broMo-, Methyl ester;5-BroMo-pyrazine-2-carboxylic acid Methyl ester;Pyrazinecarboxylic acid, 5-bromo-, methyl ester
• CAS NO: 210037-58-4
• Molecular Formula: C6H5BrN2O2
• Molecular Weight: 217.03
• Mol File: 210037-58-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 289℃
• Flash Point: 129℃
• Appearance: /Solid
• Density: 1.669
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.69±0.10(Predicted)
• CAS DataBase Reference: METHYL 5-BROMOPYRAZINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-BROMOPYRAZINE-2-CARBOXYLATE(210037-58-4)
• EPA Substance Registry System: METHYL 5-BROMOPYRAZINE-2-CARBOXYLATE(210037-58-4)

Safety Data

• Hazardous Substances Data: 210037-58-4(Hazardous Substances Data)

Usage

General Description

Methyl 5-bromopyrazine-2-carboxylate is a chemical compound with the molecular formula C7H6BrN2O2. It is a derivative of pyrazine and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. methyl 5-bromopyrazine-2-carboxylate is a brominated ester of 2-carboxypyrazine and is typically used as a building block for the creation of more complex organic molecules. Methyl 5-bromopyrazine-2-carboxylate has potential applications in the fields of medicinal chemistry and crop protection due to its ability to be modified into various biologically active compounds. However, it is important to handle this chemical with care and follow appropriate safety protocols due to its potential hazards.

Upstream product

• 36070-80-1 5-chloropyrazinoic acid 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 
• 13924-95-3 5-hydroxy-pyrazine-2-carboxylic acid methyl ester 

Downstream Products

• 1174321-06-2 5-(difluoromethyl)pyrazine-2-carboxylic acid 
• 1388651-30-6 N-(3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide 
• 1262803-64-4 methyl 5-(hydroxymethyl)pyrazine-2-carboxylate 
• 1419609-94-1 1-(((5S,7S)-3-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H- benzo[d]imidazole-6-carbonitrile 

Relevant articles and documents

Synthesis of BACE1 Inhibitors E2609 / E2071 via Oxime-Olefin Cycloaddition following a Process Risk Mitigation Strategy

Process development of E2609 from the preclinical stage to the clinical stage following a process risk mitigation strategy is described here. Key features include a turbo Grignard reaction monitored by in-situ IR, [3 + 2] cycloaddition in water, chemoselective amide coupling via in-situ protection, and a Reformatsky/decarboxylation approach to install a difluoromethyl group. Toward safe and scalable manufacture of E2071, an analog of E2609, a flow-reaction process for trifluoromethylation of aldehydes is presented here.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.